Pharminent

Boehringer signs COPD research deal with Weill

Boehringer Ingelheim and Weill Cornell Medicine are working together to identify novel treatment approaches that could halt or even reverse lung tissue damage in coronary obstructive pulmonary disorder (COPD). http://www.pharmatimes.com/news/boehringer_signs_copd_research_deal_with_weill_1186847

Filed under: COPD